Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
294.9 USD | -0.19% | -2.37% | -10.42% |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company benefits from high valuations in earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.42% | 17.5B | A- | ||
+7.77% | 218B | B | ||
+10.16% | 189B | B- | ||
+26.21% | 151B | B- | ||
+32.78% | 113B | A- | ||
+1.98% | 64.02B | A- | ||
+14.48% | 52.6B | B+ | ||
+2.92% | 49.85B | B+ | ||
-6.60% | 37.89B | A | ||
-1.07% | 34.92B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- WAT Stock
- Ratings Waters Corporation